Short-term administration of (-)-epigallocatechin gallate reduces hepatic steatosis and protects against warm hepatic ischemia/reperfusion injury in steatotic mice.
Hepatic steatosis increases the extent of cellular injury incurred during ischemia/reperfusion (I/R) injury. (-)-Epigallocatechin gallate (EGCG), the major flavonoid component of green tea (camellia sinensis) is a potent antioxidant that inhibits fatty acid synthase (FAS) in vitro. We investigated the effects of EGCG on hepatic steatosis and markers of cellular damage at baseline and after I/R injury in ob/ob mice. Animals were pretreated with 85 mg/kg EGCG via intraperitoneal (ip) injection for 2 days or oral consumption in the drinking water for 5 days before 15 minutes of warm ischemia and 24 hours of reperfusion. After EGCG administration, total baseline hepatic fat content decreased from baseline. Palmitic acid and linoleic acid levels also were reduced substantially in all ECGC-treated animals before I/R. Alanine aminotransferase (ALT) levels decreased in all EGCG-treated animals compared with control animals after I/R. Histologic analysis demonstrated an average decrease of 65% necrosis after EGCG administration. EGCG administration also increased resting hepatic energy stores as determined by an increase in cellular adenosine triphosphate (ATP) with a concomitant decrease in uncoupling protein 2 (UCP2) before I/R. Finally, there was an increased level of glutathione (GSH) in the EGCG-treated mice compared with the vehicle-treated mice both at baseline and after I/R. In conclusion, taken together, this study demonstrates that treatment with ECGC by either oral or ip administration, significantly protects the liver after I/R, possibly by reducing hepatic fat content, increasing hepatic energy status, and functioning as an antioxidant.
Fiorini
Ryan N
RN
Department of Surgery, Division of Transplant Surgery, Medical University of South Carolina, Charleston, SC 29425, USA.
Donovan
Jennifer L
JL
Rodwell
David
D
Evans
Zachary
Z
Cheng
Gang
G
May
Harold D
HD
Milliken
Charles E
CE
Markowitz
John S
JS
Campbell
Crystal
C
Haines
Julia K
JK
Schmidt
Michael G
MG
Chavin
Kenneth D
KD
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D001835:Body Weight; D002392:Catechin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004195:Disease Models, Animal; D002149:Energy Intake; D004734:Energy Metabolism; D005234:Fatty Liver / Q000473:pathology / Q000517:prevention & control*; D022781:Hepatocytes / Q000473:pathology; D008099:Liver / Q000098:blood supply*; D008102:Liver Circulation; D008297:Male; D051379:Mice; D008820:Mice, Obese; D009336:Necrosis; D015427:Reperfusion Injury / Q000473:pathology / Q000517:prevention & control*
D000975:Antioxidants; D002392:Catechin; C045651:epigallocatechin gallate